NCT06068335Recruiting
Innate Immunity in Allergic Asthma
Source: ClinicalTrials.gov · Last updated 6 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 28 Sept 2023
- Start date
- 18 Oct 2021
- Primary completion date
- Jun 2025
- Lead sponsor
- University of Central Florida
- Diseases
- Asthma
- NCT number
- NCT06068335
What you commit to
- Study type: Observational
- Planned participants: 100
- From 18 Oct 2021 to the primary completion date, Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.
Other
- Pregnant women and prisoners will be excluded from the study.
Who the study is looking for
- Participants must be at least 18 years of age
- no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Central Florida Coordinator of this site? Confirm its status | Orlando | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.